A Phase I/II Multicenter Open-label Dose Escalation Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy

Trial Profile

A Phase I/II Multicenter Open-label Dose Escalation Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Cerebroside-sulfatase (Primary)
  • Indications Metachromatic leukodystrophy
  • Focus Adverse reactions; First in man
  • Acronyms IDEAMLD
  • Sponsors Shire
  • Most Recent Events

    • 31 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 13 Apr 2016 Status changed from recruiting to active, no longer recruiting.
    • 08 Oct 2015 Status changed from active, no longer recruiting to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top